Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Tsuji

Showing results (1141-1150 of 1,208) with videos related to

Pageof 121
Sort By:
The Journal of International Medical Research|January 1, 1982
Therapeutic effects of tiopronin on chronic hepatitis: a double-blind clinical studyF Ichida, K Shibasaki, T Takino, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiBrian M Ho, Jingxiu Jin, Jacob T Sanborn, et al.
The Lancet. Microbe|July 1, 2022
Research priorities towards precision antibiotic therapy to improve patient careZackery P Bulman, Sebastian G Wicha, Elisabet I Nielsen, et al.
Nature Immunology|March 23, 2001
Fc alpha/mu receptor mediates endocytosis of IgM-coated microbesA Shibuya, N Sakamoto, Y Shimizu, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelZakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumanniiJustin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
Antimicrobial Agents and Chemotherapy|August 4, 2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane IntegrityNicholas M Smith, Katie Rose Boissonneault, Liang Chen, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Pharmacotherapy|February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Pageof 121

Showing results (1141-1150 of 1,208) with videos related to

Sort By:
Pageof 121
The Journal of International Medical Research|January 1, 1982
Therapeutic effects of tiopronin on chronic hepatitis: a double-blind clinical studyF Ichida, K Shibasaki, T Takino, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2025
Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiBrian M Ho, Jingxiu Jin, Jacob T Sanborn, et al.
The Lancet. Microbe|July 1, 2022
Research priorities towards precision antibiotic therapy to improve patient careZackery P Bulman, Sebastian G Wicha, Elisabet I Nielsen, et al.
Nature Immunology|March 23, 2001
Fc alpha/mu receptor mediates endocytosis of IgM-coated microbesA Shibuya, N Sakamoto, Y Shimizu, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelZakuan Z Deris, Heidi H Yu, Kathryn Davis, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2016
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumanniiJustin R Lenhard, Jürgen B Bulitta, Terry D Connell, et al.
Antimicrobial Agents and Chemotherapy|August 4, 2022
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane IntegrityNicholas M Smith, Katie Rose Boissonneault, Liang Chen, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Pharmacotherapy|February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Pageof 121